Eganelisib

N/A

Report date: 2024/04/11 12:01:09
NME

Base Information

Drug NameEganelisib
Drug Alias NameIPI-549
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase gamma inhibitors
TargetsPhosphatidylinositol-4,5-Bisphosphate 3 kinase gamma
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesUrinary Bladder Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntellikine LLC
China Registration ClassN/A

Develop Information

Active CompaniesStelexis BioSciences LLCInfinity Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesUrinary Bladder Neoplasms +[7] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[7] 

Other Information

ATC CodeN/A
Related LinksN/A